The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer-Reference-Cited by-同舟云学术

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer

Published:2016-12-09 Issue:5 Volume:8 Page:7666-7677
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Khelwatty Said¹,Essapen Sharadah¹²,Bagwan Izhar³,Green Margaret³,Seddon Alan¹,Modjtahedi Helmout¹

Affiliation:

1. School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston UK

2. St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK

3. Department of Histopathology, Royal Surrey County Hospital, Guildford, UK

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis;iScience;2022-05

2. HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer;Cancers;2021-02-05

3. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer;Cancer Science;2020-07-20

4. Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer;Growth Factors;2020-07-03

5. Metastatic Colorectal Cancer: Prognostic and Predictive Factors;Current Medicinal Chemistry;2020-06-04